AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Caribou Biosciences, Inc.
Video analysis: CRBU
All videosNo video analysis for this stock yet. Request one from our team.
News: CRBU
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU
BlackRock Inc. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ: CRBU) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,815,843 shares of the company's stock, valued at approximately $13,756,000. BlackRock Inc. owned about 7.88% of Caribou Biosciences
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75
Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 -- BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter of 2026 and provided a business update.
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the H.C.
